Dragonfly Therapeutics Announces All Rights Revert to Dragonfly for DF6002, its Proprietary IL12 Investigational Immunotherapy Program February 22, 2023
THIO + Atezolizumab or Pembrolizumab demonstrated Significantly Greater Tumor Inhibition February 22, 2023
Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Gen Anti-MUC1-C Agents for Drug-Resistant Cancers February 8, 2023
Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment February 8, 2023
Teon Therapeutics Announces Clinical Trial Collaboration With Merck to Evaluate TT-81 in Combination with KEYTRUDA February 1, 2023
TC BioPharm and The University of Texas MD Anderson Cancer Center Announce Strategic Collaboration to Advance Gamma Delta T Cells in Oncology February 1, 2023
First Patient dosed in Ph I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors February 1, 2023
FDA Clears IND Application for Ph 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors February 1, 2023
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology January 17, 2023
IND approved for MUC1*-CAR-1XX with Increased Persistence and Ability to Kill Low Antigen Expressing Cells for Treatment of Solid Tumor Cancers January 17, 2023
Triumvira Immunologics and Merck to Evaluate TAC01-HER2 Cell Therapy + KEYTRUDA in Patients with HER2+ve Solid Tumors January 11, 2023
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets January 11, 2023
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for 7 Investigational ADC Candidates for the Treatment of Cancer January 4, 2023
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics January 4, 2023
Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck to Develop Novel Immunosynthen ADCs January 4, 2023
Anocca secures EUR 25 million from the European Investment Bank (EIB) to support clinical development of next-generation T-cell therapies for cancer January 4, 2023
mOS of 21 Months in Advanced, Refractory Cancer Patients observed in Ph 2 trial of PDS0101-based triple combination therapy in advanced HPV-positive cancers January 4, 2023
Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy December 13, 2022
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors December 13, 2022
